Showing 1581-1590 of 2494 results for "".
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- New Study Shows Intraocular Lens Centration and Stability May Be Improved When Zepto Capsulotomy Platform is Used with Purkinje Reflectionshttps://modernod.com/news/new-study-shows-intraocular-lens-centration-and-stability-may-be-improved-when-zepto-capsulotomy-platform-is-used-with-purkinje-reflections/2480912/Centricity Vision announced the publication of a clinical study describing how to use Purkinje reflections at patient fixation for capsulotomy centration and 360-degree capsular overlap with the Zepto platform to help achieve improved visual outcomes. Published in the Journal
- Lilly, Incyte’s Olumiant Cuts Recovery Time When Added to Veklury in Hospitalized COVID-19 Patientshttps://modernod.com/news/lilly-incytes-olumiant-cuts-recovery-time-when-added-to-veklury-in-hospitalized-covid-19-patients/2478281/Eli Lilly and Incyte reported Monday that the JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) met the primary endpoint of the ACTT 2 study by significantly reducing the time to recovery compared to Veklury alone in hospitalized patients w
- Aerpio Pharmaceutical’s AKB-9778 Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandinhttps://modernod.com/news/aerpio-pharmaceuticals-akb-9778-produced-iop-lowering-with-minimal-hyperemia-when-combined-with-prostaglandin/2477211/Aerpio Pharmaceuticals announced new results from the fifth cohort of subjects from a phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients in that cohort with ocular hypertension (OHT) or primary open angle glaucoma (POAG).<
- New Dates Set for Vision Expo East 2021https://modernod.com/news/new-dates-for-vision-expo-east-2021/2478371/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced that Vision Expo East 2021, originally scheduled to take place from March 18–21, will now take place May 25–28, 2021 (Education: May 25–28; Exhibition: May 26–28) at the Javits Center in New York City. The date change r
- Heru Releases re:Vive 2.0: A Single Wearable Platform with 6 Vision Diagnostic Modalities that Support 5 CPT Codeshttps://modernod.com/news/heru-releases-revive-20-a-single-wearable-platform-with-6-vision-diagnostic-modalities-that-support-5-cpt-codes/2480396/Heru announced it is expanding the capabilities of re:Vive by Heru, the company’s wearable gamified diagnostic solution, to include three new testing modalities: Color Vision CPT 92283, Contrast Sensitivity, and Dark Adaptation CPT 92284. “Since the inception of Heru, our go
- NovaSight Announces Establishment of Three Unique CPT Codes for the CureSight Digital Treatment for Lazy Eyehttps://modernod.com/news/novasight-announces-establishment-of-three-unique-cpt-codes-for-the-curesight-digital-treatment-for-lazy-eye/2479343/NovaSight announced that it has reached several key milestones that signal progress toward the launch of its CureSight digital treatment device for amblyopia (lazy eye) and the establishment of a reimbursement structure for the physicians and patients who use it. NovaSight took an importan
- Alcon Presents Comprehensive Scientific Program With 59 Abstracts at ESCRS 2022https://modernod.com/news/alcon-presents-comprehensive-scientific-program-with-59-abstracts-at-escrs-2022/2481096/Alcon will present extensive data during the 2022 Congress of the European Society of Cataract and Refractive Surgery (ESCRS), a hybrid event taking place both virtually and in Milan, Italy, September 16-20. The official program will feature 59 abstracts, with more than 30 focused on Alcon’
- Tarsus Pharmaceuticals Appoints Wendy Yarno to Board of Directorshttps://modernod.com/news/tarsus-pharmaceuticals-appoints-wendy-yarno-to-board-of-directors/2478584/Tarsus Pharmaceuticals announced the appointment of Wendy L. Yarno to its Board of Directors and its audit committee. Ms. Yarno has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck &a
- Johnson & Johnson Vision to Showcase New Products, Data, Educational Opportunities, and Charitable Giving at 2018 AAOhttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-products-data-educational-opportunities-and-charitable-giving-at-2018-aao/2479756/Johnson & Johnson Vision will showcase the company’s leadership in eye health, innovation and giving at the 2018 American Academy of Ophthalmology’s Annual Meeting (AAO) in Chicago, October 26-30. Johnson & Johnson Vision invented many of the treatments changing the trajectory of e